Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2003

View Archived Issues

Iptakalim, a novel antihypertensive agent, evaluated in rats and dogs

New data on the molecular mechanisms underlying the antitumor activity of MS-275

Raloxifene reduces likelihood of developing osteoporosis and demonstrates uterine safety

Selective iNOS inhibitors show potential in the treatment of endotoxin-induced uveitis

Fluoratec, a DAT imaging agent in clinical development

NS-2330 clinical program extended to Japan

PharmaCare selected as national distributor for Synagis

Aptamera and Archemix enter development and license agreement for AGRO-100

AVI Biopharma seeks orphan drug designation for AVI-4179 in SARS

Change Technology Partners and Neurologix to merge

Genzyme submits regulatory submission for Hylaform

New phase III trial of loteprednol etabonate for allergic rhinitis

Generex receives SBIR grant for HER-2/neu peptide vaccine for breast cancer

Patent Discovery Corp. acquires ADDE rights

New safety information for salmeterol-based drugs

Nymox reviews pipeline

New topoisomerase inhibitors for use in bacterial or fungal infections and cancer

Dual adenosine A1/A2A receptor antagonists and their use claimed by Fujisawa

Japanese researchers isolate new antiinflammatory and antitumor terpenes from plant roots

Schering-Plough and Pharmacopeia team describes new CXC receptor antagonists

Merck patent covers novel insulin receptor kinase activators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...